PMID- 26823883
OWN - NLM
STAT- MEDLINE
DCOM- 20161024
LR  - 20181202
IS  - 1936-2625 (Electronic)
IS  - 1936-2625 (Linking)
VI  - 8
IP  - 11
DP  - 2015
TI  - Acute promyelocytic leukemia with cryptic t(15;17) on isochromosome 17: a case 
      report and review of literature.
PG  - 15294-300
AB  - Acute Promyelocytic Leukemia (APL) is one of the most curable leukemia which 
      shows great sensitivity to all-trans retinoic acid (ATRA) although a small number 
      of the patients present poor prognosis and short survival. Isochromosome 17 in 
      APL which usually bears an additional copy of RARA/PML fusion gene is considered 
      to be a negative factor on its prognosis. Cryptic t(15;17) on i(17q) leads to an 
      extra copy of PML/RARA rather than RARA/PML which may confer a worse prognosis. 
      We describe here a rare APL case with complex chromosomal abnormality including 
      isochromosome 17 bearing cryptic t(15;17) showing poor outcome. The patient lacks 
      a classic t(15;17) and fluorescence in situ hybridization (FISH) presents 2 
      PML/RARA fusion signals on both long arms of the isochromosome. The patient also 
      acquired a secondary mutation at relapse when the initial karyotype was already a 
      complex karyotype involving chromosome 13, 17 and 22 at the same time. The poor 
      response of this patient to traditional chemotherapy like ATRA and novel therapy 
      like arsenic trioxide (ATO) suggests that early auto-hematological stem cell 
      transplantation may be the choice of APL with isochromosome 17 especially with 
      cryptic t(15;17) on i(17q). We are the first to show a clear history and evidence 
      of FISH of these kind of cases. A small summary of cases with cryptic t(15;17) on 
      isochromosome 17 is also made.
FAU - Tang, Yuting
AU  - Tang Y
AD  - Department of Hematology, Tongji Hospital of Tongji Medical College, Huazhong 
      University of Science and Technology 1095 Jie-Fang Avenue, Wuhan 430030, Hubei, 
      P. R. China.
FAU - Wang, Ying
AU  - Wang Y
AD  - Department of Hematology, Tongji Hospital of Tongji Medical College, Huazhong 
      University of Science and Technology 1095 Jie-Fang Avenue, Wuhan 430030, Hubei, 
      P. R. China.
FAU - Hu, Liang
AU  - Hu L
AD  - Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong 
      University of Science and Technology 1095 Jie-Fang Avenue, Wuhan 430030, Hubei, 
      P. R. China.
FAU - Meng, Fankai
AU  - Meng F
AD  - Department of Hematology, Tongji Hospital of Tongji Medical College, Huazhong 
      University of Science and Technology 1095 Jie-Fang Avenue, Wuhan 430030, Hubei, 
      P. R. China.
FAU - Xu, Danmei
AU  - Xu D
AD  - Department of Hematology, Tongji Hospital of Tongji Medical College, Huazhong 
      University of Science and Technology 1095 Jie-Fang Avenue, Wuhan 430030, Hubei, 
      P. R. China.
FAU - Wan, Kai
AU  - Wan K
AD  - Department of Hematology, Tongji Hospital of Tongji Medical College, Huazhong 
      University of Science and Technology 1095 Jie-Fang Avenue, Wuhan 430030, Hubei, 
      P. R. China.
FAU - Huang, Lifang
AU  - Huang L
AD  - Department of Hematology, Tongji Hospital of Tongji Medical College, Huazhong 
      University of Science and Technology 1095 Jie-Fang Avenue, Wuhan 430030, Hubei, 
      P. R. China.
FAU - Li, Chunrui
AU  - Li C
AD  - Department of Hematology, Tongji Hospital of Tongji Medical College, Huazhong 
      University of Science and Technology 1095 Jie-Fang Avenue, Wuhan 430030, Hubei, 
      P. R. China.
FAU - Zhou, Jianfeng
AU  - Zhou J
AD  - Department of Hematology, Tongji Hospital of Tongji Medical College, Huazhong 
      University of Science and Technology 1095 Jie-Fang Avenue, Wuhan 430030, Hubei, 
      P. R. China.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20151101
PL  - United States
TA  - Int J Clin Exp Pathol
JT  - International journal of clinical and experimental pathology
JID - 101480565
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Arsenicals)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (Oxides)
RN  - 0 (promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein)
RN  - 5688UTC01R (Tretinoin)
RN  - S7V92P67HO (Arsenic Trioxide)
SB  - IM
MH  - Antineoplastic Agents/therapeutic use
MH  - Arsenic Trioxide
MH  - Arsenicals/therapeutic use
MH  - Bone Marrow Examination
MH  - *Chromosomes, Human, Pair 15
MH  - *Chromosomes, Human, Pair 17
MH  - Disease Progression
MH  - Fatal Outcome
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - *Isochromosomes
MH  - Karyotype
MH  - Leukemia, Promyelocytic, Acute/drug therapy/*genetics/pathology
MH  - Male
MH  - Molecular Diagnostic Techniques
MH  - Mutation
MH  - Oncogene Proteins, Fusion/genetics
MH  - Oxides/therapeutic use
MH  - Phenotype
MH  - Predictive Value of Tests
MH  - Time Factors
MH  - *Translocation, Genetic
MH  - Treatment Outcome
MH  - Tretinoin/therapeutic use
MH  - Young Adult
PMC - PMC4713669
OTO - NOTNLM
OT  - Acute promyelocytic leukemia
OT  - complex karyotype
OT  - cryptic insertion
OT  - isochromosome 17
EDAT- 2016/01/30 06:00
MHDA- 2016/10/25 06:00
PMCR- 2015/11/01
CRDT- 2016/01/30 06:00
PHST- 2015/09/09 00:00 [received]
PHST- 2015/10/23 00:00 [accepted]
PHST- 2016/01/30 06:00 [entrez]
PHST- 2016/01/30 06:00 [pubmed]
PHST- 2016/10/25 06:00 [medline]
PHST- 2015/11/01 00:00 [pmc-release]
PST - epublish
SO  - Int J Clin Exp Pathol. 2015 Nov 1;8(11):15294-300. eCollection 2015.